Retreatment with full-dose cytarabine in a patient with previous neurological toxicity.

Abstract

INTRODUCTION:

Cytarabine is one of the main chemotherapy drugs used to treat hematological malignancies. Neurotoxicity is an increasingly recognized adverse effect of high-dose cytarabine therapy and occurs in 10% to 25% of patients. There is very little experience with cytarabine retreatment following neurotoxicity.

CASE REPORT:

We report a case of a man who was diagnosed with chemotherapy-induced cerebellar syndrome. He was treated with high doses of cytarabine.

MANAGEMENT AND OUTCOME:

The patient was successfully retreated at full dose after experiencing cytarabine-induced cerebellar toxicity during the first cycle of a chemotherapy regimen. He did not develop any neurological complications and successfully underwent hematopoietic stem cell transplantation. He is currently in complete remission and free of disease.

DISCUSSION:

This original case report assesses the possibility of retreatment without the need for dose reduction.

• Authors: Núria Meca Casasnovas, Alba Manzaneque, Ana Muntañola, Genís Castells
• Journal: Journal of oncology pharmacy practice : official publication of the International Society of Oncology Pharmacy Practitioners (J Oncol Pharm Pract) Vol. 28 Issue 7 Pg. 1634-1636 (Oct 2022) ISSN: 1477-092X [Electronic] England
• PMID: 35102789 (Publication Type: Case Reports, Journal Article)

Chemical References

• Cytarabine

Topics

• Antineoplastic Combined Chemotherapy Protocols
• Cytarabine (adverse effects)
• Hematopoietic Stem Cell Transplantation
• Humans
• Leukemia, Myeloid, Acute (etiology)
• Male
• Remission Induction
• Retreatment